Ambu A/S (LON:0MJF)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 2.12B -28.7% |
| Revenue (ttm) | 718.34M +4.7% |
| Net Income | 58.74M +42.1% |
| EPS | 0.22 +43.1% |
| Shares Out | n/a |
| PE Ratio | 36.10 |
| Forward PE | 24.43 |
| Dividend | 0.05 (0.58%) |
| Ex-Dividend Date | Dec 4, 2025 |
| Volume | 23,056 |
| Open | 70.65 |
| Previous Close | 70.95 |
| Day's Range | 70.20 - 72.35 |
| 52-Week Range | 56.40 - 111.80 |
| Beta | 1.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also prov... [Read more]
Financial Performance
In fiscal year 2025, Ambu A/S's revenue was 6.04 billion, an increase of 11.98% compared to the previous year's 5.39 billion. Earnings were 609.00 million, an increase of 159.15%.
Financial numbers in DKK Financial StatementsNews
Ambu A/S Transcript: Q3 25/26
Q3 saw 10.3% organic growth, led by 16% expansion in Endoscopy Solutions, now 64% of revenue. EBIT margin reached 13.5%, with full-year guidance at the upper end of 12%-14%. Strong cash flow and continued innovation support a positive outlook, despite FX and tariff headwinds.
Ambu A/S Quarterly report: Q3 2026
Ambu A/S has published its Q3 2026 quarterly earnings report on August 26, 2026.
Ambu A/S Slides: Q3 2026
Ambu A/S has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 26, 2026.
Ambu downgraded to Sell from Hold at Danske Bank
Danske Bank downgraded Ambu (AMBFF) to Sell from Hold with a price target of DKK 58, down from DKK 70. The firm is more cautious on the company’s near-term outlook…
Ambu A/S Transcript: Q2 25/26
Endoscopy Solutions drove strong growth, offsetting A&PM declines, with guidance narrowed to 10%-12% revenue growth and EBIT margin maintained at 12%-14%. Share buyback expanded to DKK 450 million, and H2 is expected to see higher growth and margins.
Ambu A/S Quarterly report: Q2 2026
Ambu A/S has published its Q2 2026 quarterly earnings report on May 6, 2026.
Ambu A/S Slides: Q2 2026
Ambu A/S has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 6, 2026.
Ambu A/S Transcript: Q1 25/26
Q1 delivered 8.6% organic revenue growth, led by endoscopy (14.4%) and strong urology/respiratory momentum. EBIT margin was 10.5% (adjusted >15% excluding tariffs/FX), with full-year guidance maintained and tariff/FX headwinds expected to ease in H2.
Ambu A/S Quarterly report: Q1 2026
Ambu A/S has published its Q1 2026 quarterly earnings report on February 4, 2026.
Ambu A/S Slides: Q1 2026
Ambu A/S has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 4, 2026.
Ambu A/S Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong double-digit growth and a successful turnaround have positioned the company as a leader in single-use endoscopy, with a focus on respiratory and urology. Innovation, scalable operations, and a robust financial outlook support continued expansion, while competition and market conversion drive future growth.
Ambu A/S Slides: SEB Nordic Seminar presentation
Ambu A/S has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.
Ambu A/S Transcript: Q4 24/25
Delivered 13.1% organic revenue growth and 13.0% EBIT margin, driven by strong endoscopy and anesthesia segments. Outlook for 2025-2026 is 10%-13% organic growth and 12%-14% EBIT margin, with tariffs and FX as key headwinds but long-term targets reaffirmed.
Ambu A/S Annual report: Q4 2025
Ambu A/S has published its Q4 2025 annual report on November 5, 2025.
Ambu A/S Quarterly report: Q4 2025
Ambu A/S has published its Q4 2025 quarterly earnings report on November 5, 2025.
Ambu A/S Slides: Q4 2025
Ambu A/S has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on November 5, 2025.
Ambu A/S Transcript: CMD 2025
Ambu unveiled its ZOOM AHEAD strategy, targeting global leadership in single-use endoscopy with a focus on innovation, digital solutions, and sustainability. Long-term guidance was raised to 11%-13% organic revenue CAGR and over 20% EBIT margin by 2029/2030, supported by strong market growth, operational scale, and disciplined M&A.
Ambu A/S Slides: FY 2025
Ambu A/S has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 1, 2025.
Ambu initiated with a Buy at UBS
UBS analyst Thyra Lee initiated coverage of Ambu (AMBFF) with a Buy rating and DKK 147 price target The company is set to deliver mid-teens sales and mid-20s earnings growth,…
ANNUAL REPORT 2022/23 (EARNINGS RELEASE)
For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high d...
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S...